HT
XENE icon

Headlands Technologies’s Xenon Pharmaceuticals XENE Stock Holding History

Headlands Technologies’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Buy
+6,120
New +$282K 0.04% 452
2024
Q1 		– Sell
-23
Closed -$1.06K – 1588
2023
Q4 		$1.06K Sell
23
-4
-15% -$141 ﹤0.01% 898
2023
Q3 		$922 Buy
+27
New +$1.01K ﹤0.01% 860

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Headlands Technologies's XENE Position: Q1 2026 in Review

Headlands Technologies opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 6,120 shares worth $356K. The stake represents 0.04% of the portfolio and ranks #452 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in XENE as recently as Q4 2023.

Headlands Technologies first reported a position in XENE in Q3 2023 and has held it in 3 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Headlands Technologies held 6,120 shares of Xenon Pharmaceuticals worth $356K as of Q1 2026.
  • Xenon Pharmaceuticals was a new Headlands Technologies position in Q1 2026.
  • Xenon Pharmaceuticals made up 0.04% of Headlands Technologies's portfolio in Q1 2026, its #452 holding.
  • Headlands Technologies first reported a position in Xenon Pharmaceuticals in Q3 2023 and has held it in 3 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.